| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/089198879600900101 |
| P698 | PubMed publication ID | 8679057 |
| P2093 | author name string | J L Cummings | |
| D I Kaufer | |||
| D Christine | |||
| P2860 | cites work | The Stockton Geriatric Rating Scale | Q51232807 |
| Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. | Q52057810 | ||
| A new rating scale for Alzheimer's disease. | Q53197509 | ||
| Physostigmine ameliorates the delusions of Alzheimer's disease. | Q53210078 | ||
| Tacrine in Alzheimer's disease | Q56763713 | ||
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| The cholinergic hypothesis of geriatric memory dysfunction | Q28277644 | ||
| Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain | Q34714755 | ||
| Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine | Q35168053 | ||
| The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory | Q36489645 | ||
| Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study | Q38489258 | ||
| The cholinergic hypothesis--ten years on. | Q39729362 | ||
| Cholinergic function and intellectual decline in Alzheimer's disease | Q39749652 | ||
| Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? | Q40592040 | ||
| Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations | Q41186702 | ||
| Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase | Q42193896 | ||
| A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group | Q44110810 | ||
| Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial | Q46853941 | ||
| Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials | Q48120134 | ||
| The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease | Q48391011 | ||
| A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group | Q48418557 | ||
| Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 | ||
| P433 | issue | 1 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 1-6 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Journal of Geriatric Psychiatry and Neurology | Q6295256 |
| P1476 | title | Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study | |
| P478 | volume | 9 |
| Q42623834 | A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease |
| Q35236228 | A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease |
| Q43885713 | A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting |
| Q33650561 | Acetylcholine in mind: a neurotransmitter correlate of consciousness? |
| Q73239015 | Alzheimer's Disease |
| Q34160761 | Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies |
| Q34192420 | Alzheimer's disease: current and future therapeutic perspectives |
| Q30310930 | Alzheimer's disease: current pharmacotherapy in the context of patient and family needs |
| Q50866513 | An economic evaluation of donepezil in the treatment of Alzheimer's disease. |
| Q34987695 | Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. |
| Q28260488 | Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial |
| Q34655144 | Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease |
| Q35036002 | Behavior problems in demented nursing home residents: a multifaceted approach to assessment and management |
| Q34108192 | Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders |
| Q34251448 | Cholinesterase inhibitors for behavioral disturbance in dementia |
| Q33885924 | Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly |
| Q44807722 | Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response |
| Q34142818 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors |
| Q42610768 | Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study |
| Q34957392 | Cognitive and motor symptoms in dementia: focus on dementia with Lewy bodies |
| Q74457403 | Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model |
| Q34174245 | Depressive syndromes in dementia |
| Q42675662 | Determining the minimum clinically important differences for outcomes in the DOMINO trial. |
| Q38940217 | Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer's disease |
| Q46439014 | Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease? |
| Q43614971 | Donepezil in the treatment of opioid-induced sedation: report of six cases |
| Q34663361 | Donepezil use in Alzheimer disease |
| Q34150502 | Drugs for dementia: the first year. An audit of prescribing practice |
| Q42672144 | Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study |
| Q43648552 | Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease |
| Q46079295 | Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes |
| Q36922121 | Frontal-subcortical circuitry and behavior |
| Q43938849 | Galantamine and behavior in Alzheimer disease: analysis of four trials |
| Q32077293 | Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease |
| Q44060139 | Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease |
| Q41507880 | Hormone replacement therapy and other potential treatments for dementias |
| Q35226430 | Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach |
| Q92138485 | Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial |
| Q59660134 | Les symptômes psychologiques et comportementaux de la démence : description et prise en charge |
| Q33979412 | Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. |
| Q51957248 | Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. |
| Q36310524 | NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease |
| Q51961408 | Negative symptoms in the elderly patient with dementia. |
| Q34079590 | Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment |
| Q34113964 | Part VI. Primary drug therapies for Alzheimer's disease |
| Q35029479 | Pharmacologic therapy of dementia with Lewy bodies |
| Q41169288 | Pharmacologic treatment of agitation in dementia: a comprehensive review |
| Q34552380 | Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities |
| Q34146983 | Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? |
| Q42659690 | Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms |
| Q33638239 | Realistic expectations for the management of Alzheimer's disease |
| Q30327961 | Recommendations for the management of behavioral and psychological symptoms of dementia. |
| Q36562125 | Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease |
| Q53352657 | Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. |
| Q44389242 | The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure |
| Q43582607 | The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex |
| Q39455416 | Treating Alzheimer's disease. Pharmacologic options now and in the near future |
| Q35666369 | Treating Psychotic Symptoms in Elderly Patients |
| Q34262792 | Treatment of Alzheimer's disease with cholinesterase inhibitors |
| Q52168809 | Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. |
| Q52532967 | [Treatment of Alzheimer' disease: critical evaluation of the use of anticholinesterase] |
Search more.